Equity Research Pharmaceutical Preparations

Should You Buy Rafael Holdings, Inc. Stock in 2026?

By CirclFi Research Team · · 10/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Rafael Holdings, Inc. (RFL) scores 5.0/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $2.18, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 0 of 10 CirclFi valuation models project upside for Rafael Holdings, Inc. (RFL) at $2.18 — the model consensus leans bearish, with a Quality Score of 5.0/10 and Value-Trap risk of 53/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 10 of 10 models suggest overvaluation — majority bearish
  • Quality Score: 5.0/10 — Moderate — mixed signals
  • Value Trap Risk: 53/100 — Elevated — exercise caution
  • Fair Value Range: $0.03 – $2.05 (6882% spread)

Bullish Models

0 / 10

Bearish Models

10 / 10

Quality Score

5.0 /10

Moderate — mixed signals

Value Trap Risk

53 /100
Elevated

Elevated — exercise caution

Model Consensus

10 /13
Active Models

Avg. confidence: 28%

Investment Thesis

The Bull Case

Currently, no active models project meaningful upside for RFL at $2.18. Bulls might argue that qualitative factors not captured by quantitative models could unlock value not reflected in current estimates.

The Bear Case

Target: $0.03 (-98.7%)

  • According to the CirclFi Quality of Company (QOC) framework, Rafael Holdings, Inc.'s score of 5.0/10 signals fundamental weaknesses that could undermine the investment thesis.
  • According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality.
  • According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model sees the stock as overvalued with a fair value of $0.03 (-98.7%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +92.5% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: clinical trial failure represents a meaningful risk for Rafael Holdings, Inc. and its Pharmaceutical Preparations peers.

Peer Benchmarking

AZN AstraZeneca PLC
10.0
CPRX Catalyst Pharmaceuti
10.0
HRMY Harmony Biosciences
10.0
NVO Novo Nordisk A/S
10.0
SIGA SIGA Technologies In
10.0

See full Pharmaceutical Preparations rankings →

Valuation Divergence

Spread

6882%

Fair Value Range

$0.03 – $2.05

A 6882% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

PWERM

$2.05 (-6.2%)

Most Bearish

RCMH-DCF

$0.03 (-98.7%)

Key Risk Factors

Value Trap Warning

VT score 53/100 — apparent discount may mask decay.

Model Disagreement

6882% spread signals high variance in projections.

Bearish Consensus

10/10 models suggest overvaluation.

Macro/Sector Risk

Pharmaceutical Preparations headwinds could affect earnings trajectory.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View RFL Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Rafael Holdings, Inc. at $2.18. 10/10 models flag overvaluation, composite fair value sits at $0.89 (-59.1%), and the risk-reward profile appears unfavorable. Quality at 5.0/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Rafael Holdings, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy RFL stock right now?

Based on CirclFi's multi-model analysis, 0 of 10 models see upside for RFL at $2.18. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Rafael Holdings, Inc.?

Key risks include: an elevated Value Trap score of 53/100, suggesting apparent undervaluation may mask deteriorating fundamentals; wide model disagreement (6882% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.

How does RFL compare to its competitors?

Among Pharmaceutical Preparations peers, RFL holds a Quality Score of 5.0/10. Comparable companies include AZN (QOC 10.0), CPRX (QOC 10.0), HRMY (QOC 10.0). The relative ranking helps investors identify whether RFL offers better fundamental quality than alternatives in the same sector.

Is RFL a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. RFL's Quality Score of 5.0/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy RFL at?

CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $0.03 to $2.05. At $2.18, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for RFL.

View RFL Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →